Rationale: Analyses of circulating cell membrane-derived microvesicles (MV) have come under scrutiny as potential diagnostic and prognostic biomarkers of disease. However, methods to isolate, label and quantify MV have been neither systematized nor validated. Objective: To determine how pre-analytical, analytical and post-analytical factors affect plasma MV counts, markers for cell of origin and expression of procoagulant surface phosphatidylserine. Methods and results: Peripheral venous blood samples were collected from healthy volunteers and patients with cardiovascular disease and/or diabetes. Effects of blood sample collection, anticoagulant and sample processing to platelet free plasma (PFP), and MV isolation, staining and storage (freeze-thaw) and cytometer design were evaluated with replicate samples from these populations. The key finding is that use of citrate or EDTA anticoagulants decreases or eliminates microvesicles from plasma by inducing adhesion of the microvesicles to platelets or other formed elements. Protease inhibitor anticoagulants, including heparin, preserve MV counts. A centrifugation protocol was developed in which recovery of isolated MV was high with resolution down to the equivalent light scatter of 0.2 μm latex beads. Each procedure was systematically evaluated for its impact on the MV counts and characteristics. Conclusion: This study provides a systematic methodology for MV isolation, identification and quantification, essential for development of MV as diagnostic and prognostic biomarkers of disease.
Introduction
During cell activation, apoptosis or intercellular interactions, sealed unilamellar plasma membrane vesicles are shed into circulation (Lynch and Ludlam, 2007; Piccin et al., 2007; Cocucci et al., 2009 ). The terms 'microvesicles' and 'microparticles' have been interchanged, but 'microvesicles' (MV) distinguish membrane-derived vesicles from other microparticles including lipoproteins, protein aggregates, non-membranous debris, and exosomes. The concentration and composition of MV in the circulation depend upon their cells of origin and the stimuli that trigger their production. Thus, populations of circulating MV bear pathophysiological information, and so have potential for use as sensitive and specific biomarkers for presymptomatic disease. MV have been investigated for prognosis in coronary artery syndrome, aneurysm, thrombosis, pulmonary embolism, thrombotic thrombocytopenic purpura, paroxysmal nocturnal hemoglobinuria, heparin induced thrombocytopenia, sickle cell disease, sepsis, rheumatoid disease, multiple sclerosis, preeclampsia, myeloproliferative disorder and some types of cancer (Zwaal and Schroit, 1997; Berckmans et al., 2001; VanWijk et al., 2003; Morel et al., 2006; Zwicker et al., 2007; Toth et al., 2008a,b) . We reported that concentrations of platelet and endotheliumderived MV were elevated in plasma samples from recentlymenopausal women who were at low risk for cardiovascular disease by Framingham scores but who had unexpected coronary calcification (Jayachandran et al., 2008) .
Methods for isolation, identification, characterization and, especially, enumeration of circulating MV have not been validated completely. Several reviews of the topic have emphasized the need for validation of pre-analytical procedures, including anticoagulants and isolation methods, and for analytical procedures, including reagent compositions, instrument settings and calibration (Kim et al., 2002; Horstman et al., 2004; Jy et al., 2004; Michelsen et al., 2006; Enjeti et al., 2007; Lynch and Ludlam, 2007; Shet, 2008; Dey-Hazra et al., 2010; van Ierssel et al., 2010; Ayers et al., 2011; Yuana et al., 2011) . The present study was undertaken to define pre-analytical, analytical and postanalytical factors in MV analysis and to refine, standardize and validate methods for isolation, identification, quantification and characterization of MV in peripheral blood samples.
Materials and methods

Antibodies and other reagents
Annexin-V and mouse anti-human CD42a, CD61 and 62E conjugated with fluorescein isothiocynate (FITC) or Rphycoerythrin (PE) and TruCOUNT™ (4.2 μm) beads were purchased from BD Biosciences, San Jose, CA. Fluorescent latex beads (1 μm and 2 μm) were purchased from SigmaAldrich, Saint Louis, Missouri. Fluoresbrite® Microparticles (0.2 μm, 0.5 μm, 1 μm and 2 μm) were purchased from Polysciences, Inc., Warrington, PA. Soybean trypsin inhibitor was purchased from Sigma, St. Louis, MO, hirudin from CIBA GEIGY Ltd, Basle, Switzerland, and paraformaldehyde (16% solution, EM grade) from Electron Microscopy Sciences, Hatfield, PA. Blood collection tubes were purchased from Becton, Dickson and Company, Franklin Lakes, NJ.
Samples
All studies were approved by the Mayo Clinic Institutional Review Board. Blood samples were collected from 120 male and female participants (19-85 years of age) who were either apparently healthy or diagnosed with type II diabetes, coronary artery disease (CAD) with and without diabetes, or prior stroke or venous thromboembolism. These participants were selected to provide a wide range of MV counts and properties. Samples were collected through a 19 gauge butterfly needle by slow-fill syringe, and after discard of the initial 2-3 mL, dispensed into tubes containing either 15% ethylenediaminetetraacetic acid (EDTA), 3.2% NaCitrate (citrate; 0.11 M), Acid Citrate Dextrose (ACD, Solution B), sodium heparin (68 USP Units) or a mix of 1 μM hirudin plus a factor Xa inhibitor (10 μM Soybean Trypsin Inhibitor or 10 μM Tick Anticoagulant Peptide; H&S). The use of the trypsin inhibitor, which on its own is a weak anticoagulant, has supplanted that of the tick anticoagulant, no longer available. We have not established that addition of either Xa inhibitor is essential, but we have determined (unpublished observation) that factor X can become activated in plasma anticoagulated only with hirudin. Platelet P-selectin, PAC-1 binding and phosphatidylserine were determined as described (Jayachandran et al., 2008) .
Isolation of blood MV
The method is published in part (Jayachandran et al., 2008) . Essentially platelet free plasma (PFP) was prepared from anticoagulated blood by double centrifugation at 3000 ×g for 15 min. The PFP (0.5-1 mL) was centrifuged at 20,000 ×g for 30 min in an angle-head rotor. The supernatant plasma was subjected to a second centrifugation at 60,000 ×g for 30 min; this supernatant was then stored at −80°C for subsequent analysis. The MV pellet obtained from each centrifugation was reconstituted by vortex mixing (1-2 min) with 0.5-1 mL of Hanks'/HEPES (130 mM NaCl, 5.4 mM KCl 1.3 mM CaCl 2 , 0.8 mM MgSO 4 , 0.44 mM Na 2 HPO4, 20 mM HEPES, pH 7.4). All solutions were filtered twice through 0.2 μm membrane (Millipore) filters. Each washed suspension containing MV was then centrifuged again at 20,000×g or 60,000 ×g for 30 min and the resulting pellet reconstituted with 0.5 or 1 mL of fresh buffer.
Flow cytometry
Unless otherwise indicated, all analyses used a FACSCanto II cytometer (BD Biosciences, San Jose, CA). A sample of isolated MV (50 μL) was incubated with 4 μL of annexin-V-FITC and PE-conjugated mouse anti-human CD42a or CD61) for 25-30 min. These times and concentrations had been optimized by titration of each reagent. Where indicated, stained MV were fixed by dilution with 400 μL of 1% paraformaldehyde for 15 min. For calculation of counts, TruCOUNT™ beads (50 μL) were added immediately prior to analysis by flow cytometry. Gain settings were adjusted to place the TruCOUNT™ beads in the upper log for scatter. Unfiltered Isoton® II diluent from Beckman Coulter, Fullerton, CA, was used in cytometers. Compensation for channel spill was calculated using the autocompensation feature from recorded values of separate and combined unstained and single-stained MV. Auto-calculated compensation parameters were verified monthly. All antibodies were filtered twice through 0.2 μm membrane filters. Unfiltered buffers and antibodies contain interfering numbers of chemical microparticles (data not shown). MV are defined in this study as events b1 μm in diameter and positive for annexin-V and cell-specific markers. The thresholds were set with isotype control fluorescent antibodies. MV prepared and stained in phosphate buffered saline or HEPES buffered saline (HBS; pH 7.4) without calcium served as negative controls for annexin-V. The absolute count of MV either in the absence or presence of single or dual staining was calculated with the relation:
where G MV is the number of events in the MV gate, G TC is the number of events in the TruCOUNT™ bead gate, and TC is the number of TruCOUNT™ beads added to the sample of volume V (Shet et al., 2003; Jayachandran et al., 2008) . Except for comparison of instruments, the FACSCanto™ flow cytometer was used for all other measurements. Unless otherwise indicated data are shown as mean± SD.
Direct analysis of plasma
PFP (5 μL) was diluted 1/20 with Hanks'/HEPES (pH7.4), and then 4 μL of fluorochrome-conjugated annexin-V and cellspecific antibodies were added. These mixtures were briefly vortexed and incubated in the dark for 25-30 min at room temperature. The mixture was diluted with 800 μL of Hanks'/HEPES or buffered saline solution (HBS; 20 mM HEPES, 150 mM NaCl, 2.5 mM calcium) and 100 μL of TruCOUNT™ beads.
Results
Data acquisition
Side scatter events from size calibration beads of 0.2 μm, 0.5 μm, 1 μm and 2 μm were resolved from instrument noise with the 18-bit FACSCanto (10 5 -channel) flow cytometer ( Fig. 1) . Inspection of the scatter plot ( Fig. 1B) indicates that 0.2 μm is the lower limit for beads, which have a higher index of refraction, and therefore lower size threshold, than membrane vesicles (Koch et al., 1966; Foladori et al., 2008; Lacroix et al., 2010; Yuana et al., 2011) . More than 90% of MV isolated from plasma showed scatter intensities lower than that of 1 μm beads (Fig. 1C) . Fluorescence events from anti-CD42a and annexin V from within the MV scatter gate accounted for more than 99% of events (Fig. 1C) . For the sample shown in Fig. 1D , all but a small fraction (Q4) of counts were positive for both ligands, a finding typical for platelet MV (Jayachandran et al., 2008) . MV counts were calculated from the nominal number of beads added per volume of sample, with a minimum of 1000 TruCOUNT™ bead events (typically 2500) per analysis. The coefficient of variation of ten aliquots of 0.5, 1 and 2 μm beads was 7.2%, 2.6% and 2.4%, and MV counts calculated with the TruCOUNT™ internal standard were not significantly affected by flow rate.
Preanalytical issues 3.2.1. Anticoagulants
The choice of anticoagulant had a substantial impact on both platelet and endothelial MV counts (Fig. 2) . Both platelet and endothelial MV were fewer in preparations from blood collected in calcium chelating anticoagulants versus protease inhibitors. When counts were above the 90th percentile, endothelial (CD62-E positive) MV were effectively eliminated (Pb 0.003) in preparations from blood collected in sodium citrate compared to H&S. When counts were in the range typical of healthy donors, the counts for platelet MV in citrate plasma averaged 30-40% of the counts in hirudin and soy bean trypsin inhibitor (H&S; endothelial MV were not detected in plasmas from the normal donor pool). However, the ratio of annexin-V positive to negative MV was not sensitive to anticoagulant (r 2 = 0.08). MV recovery was the same from blood collected in Vacutainer or non-Vacutainer tubes containing the same concentration of calcium chelating and protease inhibitor anticoagulants (not shown). Does calcium chelation suppress MV recovery or do protease inhibitors stimulate shedding? The results with endothelial MV suggest suppression. We had observed that there was a window of as long as 10 min between phlebotomy and mixing of the blood with anticoagulant during which the MV count was stable. Accordingly, blood (1 mL aliquots) without anticoagulant was centrifuged immediately for 2 min at 8000 ×g or for 10 min at 3000 ×g, and then anticoagulants were added to these platelet poor plasmas (PPP). Addition of any anticoagulant to PPP thus prepared from non-anticoagulated blood yielded the same number of annexin-V positive MV as blood collected in H&S anticoagulant (Fig. 3) .
The basis for the loss of MV with removal of calcium was addressed by shifting the point of addition of anticoagulants. Adding either calcium chelating or protease inhibitor anticoagulants to isolated MV did not alter MV counts (data not shown). When calcium chelators were added to the platelet rich plasma (PRP) prepared from the first 800 ×g spin of blood collected in H&S or heparin (Fig. 4, top) , platelet MV counts decreased to an extent similar to that seen in whole blood with citrate or EDTA anticoagulants (Fig. 4, bottom) . In contrast, addition of H&S or heparin to PRP prepared from blood collected in calcium chelating anticoagulants did not further affect numbers of MV (Fig. 4, bottom) .
Time and temperature
Whole blood collected in either citrate or H&S was distributed into 1.5 mL tubes and maintained at either room temperature (ca. 22°C) or 33°C for up to 3 h, during which MV counts were obtained at intervals. For whole blood collected in citrate, counts of annexin-V positive and platelet MV decreased within 15 min and were significantly lower after one hour at either temperature (data not shown). In contrast, counts of annexin-V and platelet MV did not change significantly within the first hour at either temperature in blood collected in H&S but increased significantly thereafter (Fig. 5) . The increase in counts of stained MV was greater at room temperature than at 33°C. However, the percentage of platelets expressing surface P-selectin, activated glycoprotein α IIb β 3 , phosphatidylserine remained b5% in all samples. Counts of endothelial MV did not change during the three hours at either temperature.
Recovery after centrifugation
Centrifugation of PFP at 20,000 ×g recovered on average 80% of the MV measured by direct staining of PFP (r 2 =0.8). More than 90% of platelet MV were recovered after a wash with Hanks'/HEPES of MV pelleted by the 20,000×g centrifugation (n = 66). Less than 10% additional platelet MV were isolated when plasma supernatants from the 20,000×g centrifugation were centrifuged a second time at 60,000×g for 30 min. Typical of isolation procedures, the recovery increased from a low of 50% at the lowest MV counts up to 80% at the highest counts. Scatter signals from MV isolated by ultracentrifugation (Fig. 1B) were better resolved than those obtained from samples analyzed by direct staining of PFP or unwashed MV (Fig. 6) , which showed substantial populations of microparticles negative for all stains (Fig. 6, red dots) .
Storage and freeze-thaw
Counts of MV were the same when isolated from either PFP or PPP stored at either -40°C or − 80°C for more than a year. Up to three freeze thaw cycles of PFP had no effect on MV counts, irrespective of initial counts (Fig. 7) . Once isolated, counts of isolated MV were stable during storage at room temperature for 3-4 days. However, a single freeze and thaw of isolated MV at either − 20°C, −40°C or −80°C lowered the count by 10-15%. 
Analytical issues
Count calibration
The assumption that the nominal TruCOUNT™ bead count is valid was verified by a cross-check with erythrocyte counts and a validated Coulter counter (Fig. 8) . As the erythrocyte count in each sample increased above the order of the (constant) TruCOUNT™ bead concentration, the red blood cells (RBC) event rate increased in linear proportion to the RBC count while the TruCOUNT™ bead event rate declined. Because the TruCOUNT™ calibration is in the denominator (Materials and methods), the calculated erythrocyte count showed a systematic increase (solid line/symbols) above that obtained with the Coulter counter (dashed line). Extrapolation of the linear increase to the erythrocyte count of zero intersected the count axis within 5% of the Coulter counter value, and showed a systematic error of + 10% when the count rate was 1000 times that of the TruCOUNT™ rate. Because analysis with other bead calibrators has been published (Robert et al., 2008) , we analyzed mixtures of BD TruCOUNT™ beads (4.2 μm) with Beckman-Coulter Flow-Check (10 μm) beads for counts obtained by scatter and by fluorescence. In all cases, scatter and fluorescence data were congruent. Two lots of the Flow-Check beads yielded counts of 50% of nominal or less when the TruCOUNT™ count rates were of the order of 20-30/s. At lower bead dilutions (higher count rates), the BD beads yielded proportional counts whereas the Flow-Check beads were disproportionately undercounted. We did not investigate this disparity further.
Discussion
Distinct populations of circulating MV have been observed in a variety of disease conditions, often related to inflammatory processes (Zwaal and Schroit, 1997; Berckmans et al., 2001; VanWijk et al., 2003; Morel et al., 2006; Jayachandran et al., 2008 Jayachandran et al., , 2009 ). However, the potential for MV as biomarkers has been limited by inadequate validation and standardization of sample preparation, reagents and instrument parameters (Jy et al., 2004; Lynch and Ludlam, 2007) . The importance of sample acquisition and processing to obtain platelet poor plasma has been addressed (Jy et al., 2004; Shah et al., 2008; Shet, 2008; Dignat-George et al., 2009 ) but without a systematic analysis of individual parameters. The present investigation was undertaken to fill this gap in the literature by evaluating factors that affect MV analysis in terms of venous sample collection, anticoagulants, isolation techniques, staining methods and storage and cytometer settings. An important feature of the present approach was to assess all of these parameters on blood from diverse groups of healthy and diseased individuals so that findings may be generalized.
Anticoagulant
A paramount finding of this study is the impact of anticoagulants on MV recovery. Counts of platelet and endothelial MV were substantially lower in blood collected in citrate or EDTA than in blood collected in protease inhibitors, either H&S or heparin. This effect of anticoagulants was interpreted by Shah et al. (2008) as arising from microvesiculation in vitro with protease inhibitor anticoagulants. However, results of the present study provide an alternative conclusion, first because endothelial MV, which cannot be generated in blood in vitro, were effectively removed with chelation of whole blood. Therefore, the difference in MV counts obtained in calcium chelating anticoagulants compared to protease inhibiting anticoagulants reflects loss with chelation rather than gain with protease inhibitors. This conclusion is verified by the finding that adding any anticoagulant to platelet-free plasma prepared without an anticoagulant had no effect on MV counts, which were congruent with those obtained from whole blood anticoagulated by protease inhibition. Chelation-induced association of the MV with platelets is adequate to account for this phenomenon, as it can be recapitulated with PRP prepared from blood collected in protease inhibiting anticoagulants. Because the degree of loss with chelation is unpredictable, with relative proportions of annexin-V positive and negative platelet MV not falling in predictable register, all prior work on MV from blood anticoagulated by citrate, ACD and EDTA (Jy et al., 2004 ) may need reevaluation. That said, our MV counts from citrated plasma lie within the lower group of the wide range among published studies (Yuana et al., 2011) . Platelet MV counts remained constant when either H&S or heparin anticoagulated blood was maintained for up to 60 min at 33°C, and for 30 min at room temperature, but thereafter increased. The temperature effect is commensurate with the sensitivity of platelet shape change as blood cools (Tablin et al., 2000) . Counts of endothelial MV did not change over time at either temperature, to indicate that the increase reflected release of MV from the platelets.
Bead calibration
There is growing and compelling evidence that flow cytometry resolves only the largest membrane vesicles, which comprise a near-negligible portion of the total (Koch et al., 1966; Foladori et al., 2008; Zwicker et al., 2009; Lacroix et al., 2010; Yuana et al., 2010; Chandler et al., 2011; Yuana et al., 2011) . Visualization of plasma or thrombin-stimulated platelet microvesicles by atomic force microscopy (Yuana et al., 2010) indicates a median diameter of 60 nm. Counts obtained from the AFM images averaged 1000 times those obtained by flow cytometry using an isolation and staining protocol similar to ours, and which yielded similar counts. Direct measurement of placental and plasma MV by refractive index-independent particle tracking with simultaneous extraction of translational diffusion coefficients likewise detected the order of 10 7 cellular MV/μL of plasma, more than four orders of magnitude times that detected by flow cytometry (Dragovic et al., 2011) . Using synthetic microvesicles of defined size, Chandler et al. (2011) verified that the most sensitive flow cytometers cannot detect single microvesicles smaller than about 400 nm. And finally measurements of microvesicle procoagulant activity directly in plasma (Mallat et al., 2000; Owen et al., 2011) yield activities at least 3-4 orders of magnitude higher than can be accounted for by annexin-V positive microvesicle counts obtained by flow cytometry. However, microvesicle analysis by flow cytometry has yielded correlations to inflammatory and vascular pathophysiology, and continues to dominate the MV literature, so continuing standardization and validation of reagents and sample preparation remains essential in the face of the high variability among laboratories (Yuana et al., 2011) . The basis for the disparity between BD TruCOUNT™ and Beckman-Coulter calibrators is not clear. Undercounting of a calibrator might account for exceptionally high MV counts (Shah et al., 2008) . We validated the TruCOUNT™ calibration against a washed erythrocyte suspension counted with a Coulter counter. The TruCOUNT™ beads are provided in single use tubes, whereas the Flow-Check are provided in a single bottle for repetitive sampling and thus might be prone to sampling error secondary to incomplete mixing. However, we found a fresh bottle of Flow-Check beads to yield under-counts comparable to those of a nearly exhausted bottle. We did not evaluate the disparity with a cytometer other than the FACSCanto, but no theoretical basis for a cytometer-specific disparity is obvious.
Isolation and staining
Isolation of MV with 20,000 ×g centrifugation of platelet free plasma resulted in the loss of as much as 20% of the counts obtained with direct staining, but the fidelity of the signal was higher. This enhanced resolution may reflect the removal of microparticulate lipids and proteins aggregates. Although it adds a significant pre-analytical step, isolation rather than direct staining is essential for analyzing batches of samples, as plasma clogs the flow tubes and carries over. At best, a 1/200 dilution of the plasma is required for optimal staining and analysis and so decreases the sensitivity for low abundant MV signals.
Unfixed samples yielded variably fewer MV, which could arise from MV aggregation or adsorption to the sample tubes and instrument plumbing. We have not evaluated other possible inhibitors of MV loss, but there may be alternatives to paraformaldehyde, which provide acceptable inter-assay variability of b10%.
Storage
Up to three freeze-thaw cycles of PFP did not affect MV recovery. Storage of PPP (prepared by single centrifugation of PFP at 3000 ×g for 15 min) for more than a year minimally and randomly affected MV recovery.
Conclusions
Among pre-analytical procedures that affect yield and reproducibility of microvesicle analysis, choice of anticoagulant and centrifugation protocols for preparing platelet free plasma and isolated microvesicles have major influences. Other significant influences arise from time and temperature between phlebotomy and initial centrifugation, freezing of the isolated microvesicles and internal calibration. Freezing of plasma, essential for large scale studies, has no effect on the microvesicle counts.
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